ArticleApplied biochemistry and biotechnology2026
Mechanistic Study of S100A8-mediated Ferroptosis in Vascular Dementia Through the JAK2/STAT3 Pathway.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Mechanism of mesenchymal stem cell-derived exosomes in alleviating hypoxia/re-oxygenation-induced injury of oligodendrocytes].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the mechanism of S100 Calcium Binding Protein A8 (S100A8)-mediated ferroptosis in vascular dementia (VaD) via the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway.
methodsTo establish models of VaD and study microglial responses, we employed bilateral carotid artery stenosis (BCAS) in mice and oxygen-glucose deprivation (OGD) in BV2 cells, respectively. The cognitive function of mice was assessed by Morris water maze experiments. The pathological changes of brain tissue were observed by Nissl staining and luxol fast blue staining. Inflammatory cytokines were determined by enzyme-linked immunosorbent assay. The co-localization of S100A8 was identified by immunofluorescence. Ferroptosis was assessed by related indices such as intracellular Fe
resultsIn BCAS mice, cerebral hypoperfusion triggered the upregulation of S100A8 in hippocampal microglia. This upregulation showed a progressive increase following surgery, peaking at 28 days post-BCAS. Inhibition of S100A8 improved cognitive deficits, attenuated brain damage, reduced neuroinflammation, and suppressed ferroptosis in BCAS mice. In BV2 cells, S100A8 silencing alleviated inflammation and ferroptosis induced by OGD. The anti-inflammatory effects of S100A8 silencing were counteracted by Erastin but amplified by Ferrostatin-1. Furthermore, S100A8 inhibition blocked JAK2/STAT3 activation; however, the JAK2/STAT3 agonist Colivelin TFA reversed the protective effects of S100A8 silencing in OGD-treated BV2 cells.
conclusionS100A8 mediates ferroptosis in VaD via JAK2/STAT3 pathway.
Indexed as
Identifiers
41538098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.